Valuation: ABVC BioPharma, Inc.

Market Cap 24.24M 21.01M 19.7M 17.96M 33.8M 2.31B 34.34M 232M 90.56M 1.16B 91.02M 89.05M 3.86B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 26.97M 23.38M 21.92M 19.98M 37.6M 2.57B 38.2M 258M 101M 1.29B 101M 99.06M 4.3B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.2%
Yield 2024 *
-
Yield 2025 -
1 day-0.07%
1 week-5.94%
Current month-5.01%
1 month-28.93%
3 months-10.34%
6 months-42.55%
Current year-54.96%
1 week 0.89
Extreme 0.8851
1.03
1 month 0.89
Extreme 0.8851
1.38
Current year 0.88
Extreme 0.8801
2.43
1 year 0.88
Extreme 0.8801
3.4
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 23/06/2023
Chief Executive Officer 39 01/07/2015
Chief Tech/Sci/R&D Officer 72 13/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap.
20/05/22 Other

Chairman

7,908,805 26.0954%
02/08/21 Other

Director

5,949 0.0243%
02/08/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-5.94%-67.70%-53.43% 24.26M
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-4.50%-4.69%+2.82%+463.22% 28.89B
-1.14%-1.35%+46.79%+6.32% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
-0.59%+7.88%+40.87%-20.56% 18.77B
+0.35%+12.02%+257.19%+466.50% 18.41B
-1.33%-3.89%+19.58%+610.27% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
Average -0.62%+3.64%+41.51%+176.61% 26.69B
Weighted average by Cap. -0.35%+3.98%+50.95%+164.89%

Financials

2024 2025
Net sales 510K 442K 414K 378K 710K 48.63M 722K 4.88M 1.9M 24.35M 1.91M 1.87M 81.21M -
Net income -4.9M -4.25M -3.98M -3.63M -6.83M -468M -6.94M -46.91M -18.31M -234M -18.41M -18.01M -781M -7.91M -6.86M -6.43M -5.86M -11.03M -755M -11.2M -75.67M -29.54M -378M -29.69M -29.05M -1.26B
Net Debt 2.88M 2.5M 2.34M 2.14M 4.02M 275M 4.08M 27.57M 10.77M 138M 10.82M 10.59M 459M 2.73M 2.36M 2.22M 2.02M 3.8M 260M 3.86M 26.09M 10.19M 130M 10.24M 10.02M 435M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
13/08/26 $0.9594 -0.07% 94,910
12/08/26 $0.9601 -2.53% 282,221
11/08/26 $0.9850 +3.67% 123,036
10/08/26 $0.9501 -6.85% 174,958
07/08/26 $1.020 0.00% 65,905
  1. Stock Market
  2. Stocks
  3. ABVC Stock